💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dalteparin Sodium

CHEMBL1201460 Phase 4 승인됨 Oligosaccharide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A low-molecular-weight heparin that prevents and treats blood clots by inhibiting factor Xa and thrombin in the coagulation cascade. It is injected subcutaneously and used for deep vein thrombosis, pulmonary embolism prevention, and extended venous thromboembolism treatment in cancer patients.

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Hypertension Breast Cancer Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

작용 기전

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose …

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A low-molecular-weight heparin that prevents and treats blood clots by inhibiting factor Xa and thrombin in the coagulation cascade. It is injected subcutaneously and used for deep vein thrombosis, pulmonary embolism prevention, and extended venous thromboembolism treatment in cancer patients.

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Yes, Dalteparin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201460. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.